Bin-Bin Shih et al, Journal of the Chinese Medical Association, 2017
Colorectal cancer (CRC) occurs with high incidence worldwide, but is usually diagnosed in late stage with metastasis by the conventional methods. Epidermal growth factor receptor (EGFR) is overexpressed in 97% of CRC cells, serving a promising diagnostic candidate. In the present study, Cetuximab, an anti-EGFR monoclonal antibody was conjugated with an isotope chelator, diethylene triamine penta acetic acid (DTPA), labeled with 111indium (111In) and injected to tumor bearing mice. Biological distrubution was investigated by SPECT/CT imaging.
Results revealed that 111In-Cetuximab accumulated in the both small (50mm3) and large (250mm3) tumors, whereas the ratio of tumor to muscle in the large tumor was 7.5-fold. The biodistribution data indicated that the 111In-cetuximab bound to tumor specifically that was higher than that in other organs. Consequently, 111In-cetuximab is suggested to be suitable for early diagnosis and prognostic monitor of EGFR-positive CRC in further clinical practice.
Results from nanoSPECT/CT
További termékinformációkért, vagy támogatásért keresse szakértőinket!Vegye fel a kapcsolatot